 Home > Active Ingredient News > Study of Nervous System > NEJM Stroke Day: The CHANCE-2 study of Wang Yongjun's team in the Temple of Heaven opens a new era of stroke prevention!

NEJM Stroke Day: The CHANCE-2 study of Wang Yongjun's team in the Temple of Heaven opens a new era of stroke prevention!

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

benadryl medicine

meclizine medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ischemic stroke has the characteristics of high incidence, high disability, high mortality and high recurrence rate .
Secondary prevention should be started as soon as possible after stroke
.

Preventing recurrence of ischemic stroke requires the development of measures and standardized strategies for the cause and risk factors.

Ischemic stroke has the characteristics of high incidence, high disability, high mortality and high recurrence rate .

Previous CHANCE and POINT studies have suggested that the combined antiplatelet therapy of aspirin and clopidogrel can significantly reduce the 3-month ischemic event risk in patients with high-risk nondisabling ischemic cerebrovascular events

Pharmacogenomics differences such as CYP2C19, ABCB1 gene polymorphisms, etc.

In order to further compare the effects of ticagrelor and clopidogrel in the secondary prevention of stroke among carriers with CYP2C19 dysfunction, Professor Wang Yongjun’s team from Beijing Tiantan Hospital, Capital Medical University, conducted the CHANCE-2 study, and related results Published online in the New England Journal of Medicine (NEJM) on October 28, 2021
.

Researchers conducted a randomized, double-blind, placebo-controlled trial in 202 centers in China, involving patients with mild ischemic stroke or transient ischemic attack (TIA) carrying the CYP2C19 loss-of-function allele
.

Patients were assigned to receive ticagrelor (180 mg on day 1, 90 mg once a day on days 2-90) + clopidogrel placebo at a ratio of 1:1 within 24 hours after the onset of symptoms, or to receive clopidogrel Gray (300 mg on day 1, 75 mg on day 2 to 90, once a day) + ticagrelor placebo treatment; both groups received aspirin for 21 days

Test grouping process

The results showed that a total of 11255 patients were screened, 6412 patients were included in the trial, of which 3205 were assigned to the ticagrelor group and 3207 were assigned to the clopidogrel group
.

The median age of the patients was 64.

There were 191 people (6.

Differences in the main outcomes of the two groups of patients at 90 days

In Chinese patients with mild ischemic stroke or TIA carrying CYP2C19 alleles, the 90-day stroke risk after ticagrelor was slightly lower than that of clopidogrel
.

There was no difference in the risk of severe or moderate bleeding between the two groups, but the total number of bleeding events in the ticagrelor group exceeded that in the clopidogrel group

In Chinese patients with mild ischemic stroke or TIA carrying the CYP2C19 allele, the 90-day stroke risk after ticagrelor was slightly lower than that of clopidogrel

references:

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.